Pharma pulled in big Lions Health audiences with play-by-play case studies and frank talk. Dying commercial model? Creepy big data? Yes, and more.
Cannes means creativity in the advertising world, but pharma is still sitting on the sidelines.
The European Medicines Agency today recommended approval of Imraldi, a Humira biosimilar from Samsung and Biogen.
Novartis won FDA approval for Tafinlar plus Mekinist to treat lung cancer with a specific mutation.
The positive data for Roche’s Ocrevus keep on coming.
Astellas’ U.K. unit was already suspended from the Association of the British Pharmaceutical Industry. And now, that suspension has been extended.
CSL Behring has secured FDA approval for Haegarda to prevent HAE attacks in adolescents and adults.
China’s FDA joined ICH, Takeda completed new solid dosage plant, the FDA bans imports of Ipca drugs.
Just a month after FDA staff gave a ringing endorsement to Pfizer's biosimilar for Amgen's blockbuster Epogen, the agency rejected the drug.
Shingrix met its goal in a study examining whether it can protect older adults who previously received Merck’s Zostavax.